3-(4-isobutoxy-3-nitrophenyl)-5-(4-pyridyl)-1,2,4-triazole | 577778-59-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4-isobutoxy-3-nitrophenyl)-5-(4-pyridyl)-1,2,4-triazole
• 英文别名: 4-[3-[4-(2-methylpropoxy)-3-nitrophenyl]-1H-1,2,4-triazol-5-yl]pyridine
• CAS: 577778-59-7
• 化学式: C₁₇H₁₇N₅O₃
• 分子量: 339.354
• InChiKey: GJUQULNTUDILRT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  110
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  生成 3-(4-isobutoxy-3-nitrophenyl)-5-(4-pyridyl)-1,2,4-triazole
  参考文献：
  名称：

  Design, synthesis, and pharmacological and pharmacokinetic evaluation of 3-phenyl-5-pyridyl-1,2,4-triazole derivatives as xanthine oxidoreductase inhibitors

  摘要：

  In an effort to find a potent xanthine oxidoreductase (XO) inhibitor, we discovered the best compound 2-[2-(2-methoxy-ethoxy)-ethoxy]-5-[5-(2-methyl-pyridin-4-yl)-1H-[1,2,4]triazol-3-yl]-benzonitrile 28. Here, we describe the following: (1) the design, synthesis, and structure-activity relationship of a series of 3-phenyl-5-pyridyl-1,2,4-triazole derivatives by in vitro studies of XO inhibitory activity in bovine milk and in vivo studies of serum uric acid (UA) reductive activity in rats, (2) a drug interaction study by a cytochrome P450 3A4 (CYP3A4) assay, and (3) a pharmacokinetic (PK) study. Compound 28 exhibits potent XO inhibitory activity, serum UA-lowering activity in rats, weak CYP3A4 inhibitory activity, and moderate PK profile. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.10.122

文献信息

• Novel 1 2 4-triazole compound
  申请人：Nakamura Hiroshi

  公开号：US20050004175A1

  公开（公告）日：2005-01-06

  A novel 1,2,4-triazole compound which is useful as a therapeutic agent for hyperuricemia and gout due to hyperuricemia is provided. A compound is represented by the following general formula (1): wherein R 2 represents an unsubstituted or substituted pyridyl group, R 1 represents a similar pyridyl group, a pyridine-N-oxide group corresponding to these pyridyl groups, or a phenyl group, and R 3 represents hydrogen or a lower alkyl group substituted with pivaloyloxy group and R 3 bonds to a nitrogen atom in the ring. A process for production of a compound by reacting a nitrile and a hydrazide, and a therapeutic agent, particularly a xanthine oxidase inhibitor are also provided.

  提供了一种新型的1,2,4-三唑化合物，可用作治疗高尿酸血症和由高尿酸血症引起的痛风的治疗剂。该化合物由以下通式（1）表示：其中R2表示未取代或取代的吡啶基团，R1表示类似的吡啶基团，对应于这些吡啶基团的吡啶-N-氧化物基团或苯基团，而R3表示氢或取代有丁二酰氧基的低碳基团，且R3与环中的氮原子键合。还提供了通过反应腈和肼制备化合物的方法，以及治疗剂，特别是黄嘌呤氧化酶抑制剂。
• NOVEL 1,2,4-TRIAZOLE COMPOUND
  申请人：Fuji Yakuhin Co., Ltd.

  公开号：EP1471065A1

  公开（公告）日：2004-10-27

  A novel 1,2,4-triazole compound which is useful as a therapeutic agent for hyperuricemia and gout due to hyperuricemia is provided. A compound is represented by the following general formula (1): wherein R2 represents an unsubstituted or substituted pyridyl group, R1 represents a similar pyridyl group, a pyridine-N-oxide group corresponding to these pyridyl groups, or a phenyl group, and R3 represents hydrogen or a lower alkyl group substituted with pivaloyloxy group and R3 bonds to a nitrogen atom in the ring. A process for production of a compound by reacting a nitrile and a hydrazide, and a therapeutic agent, particularly a xanthine oxidase inhibitor are also provided.

  本研究提供了一种新型 1，2，4-三唑化合物，该化合物可用作高尿酸血症和高尿酸血症引起的痛风的治疗剂。化合物由以下通式（1）表示： 其中 R2 代表未取代的或取代的吡啶基，R1 代表类似的吡啶基、与这些吡啶基相应的吡啶-N-氧化物基团或苯基，R3 代表氢或被新戊酰氧基取代的低级烷基，R3 与环中的氮原子键合。本发明还提供了一种通过腈和酰肼反应生产化合物的工艺，以及一种治疗剂，特别是一种黄嘌呤氧化酶抑制剂。
• Discovery of 3-(3-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051-a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia
  作者：Takahiro Sato、Naoki Ashizawa、Koji Matsumoto、Takashi Iwanaga、Hiroshi Nakamura、Tsutomu Inoue、Osamu Nagata

  DOI：10.1016/j.bmcl.2009.08.091

  日期：2009.11

  Our previous study identified 2-[2-(2-methoxy-ethoxy)-ethoxy]-5-[5-(2-methyl-4-pyridyl)-1H-[1,2,4]-triazol-3-yl]-benzonitrile (2) as a safe and potent xanthine oxidoreductase (XOR) inhibitor for the treatment of hyperuricemia. Here, we synthesized a series of 3,5-dipyridyl-1,2,4-triazole derivatives and, in particular, examined their in vivo activity in lowering the serum uric acid levels in rats. As a result, we identified 3-(3-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole (FYX-051, compound 39) to be one of the most potent XOR inhibitors; it exhibited an extremely potent in vivo activity, weak CYP3A4-inhibitory activity and a better pharmacokinetic pro. le than compound 2. Compound 39 is currently being evaluated in a phase 2 clinical trial. (C) 2009 Elsevier Ltd. All rights reserved.
• US7074816B2
  申请人：——

  公开号：US7074816B2

  公开（公告）日：2006-07-11